Gut Microbiome, Microbial Metabolites and Cardiometabolic Risk
369,90 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

This reference work is strong informative about the role of the gut microbiome in organism metabolism and fully discusses the relationship between gut alterations and/or gut microbiome-derived metabolites and the pathogenesis of many diseases, as well as recent advances in clinical applications of microbiome and microbial effector molecules. It clearly shows how the microbiome research is a growing field in molecular and clinical sciences, due to technical advances based on high throughput genetic sequencing technologies and omics analyses that empower systems biology-based methods for…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This reference work is strong informative about the role of the gut microbiome in organism metabolism and fully discusses the relationship between gut alterations and/or gut microbiome-derived metabolites and the pathogenesis of many diseases, as well as recent advances in clinical applications of microbiome and microbial effector molecules.
It clearly shows how the microbiome research is a growing field in molecular and clinical sciences, due to technical advances based on high throughput genetic sequencing technologies and omics analyses that empower systems biology-based methods for precision health monitoring and treatment. It will help in understanding that high diversity of the microbial communities in the gut is important to preserve health and microbiome alterations, not only in nutrition associated diseases like obesity and diabetes, but also in many chronic inflammatory, cardiovascular, oncological and neurological disorders.

Written by renown experts in the field,this reference work is intended for clinicians, residents, specialists and physicians involved in the diagnosis and treatment of affected patients.

It is published as part of the SpringerReference program, which provides access to live editions constantly updated through a dynamic peer-review publishing process.
Autorenporträt
Massimo Federici is currently Professor of Internal Medicine at the University of Rome "Tor Vergata" Medical School and Director of the Center for Atherosclerosis at the Tor Vergata Medical School hospital. He trained in Endocrinology and Metabolism at the University of Rome (1999) and at the Joslin Diabetes Center (1997). Since 1999, he is actively working in both clinical and molecular research. His laboratory is focused on mechanisms causing diabetes and atherosclerosis, including the effect of gut microbiota on both diseases. He is a member of the EU-funded Florinash Consortium which is studying how the gut microbiome influences the onset and progression of metabolic dysfunction-associated steatotic liver disease (MASLD), Type 2 diabetes, and atherosclerosis in people living with obesity. Rossella Menghini is currently Associate Professor of Clinical Biochemistry at the Department of Systems Medicine, University of Rome Tor Vergata. After a Chemistry Bachelor Degree (1996), she has been Research Fellow at the Department of Cell and Developmental Biology of the "Sapienza" University of Rome, where she obtained a Board Certification in Chemical Science. She has been Visiting Scientist at the Department of Cellular Microbiology and Immunology of the Vienna Biocentrum, Austria. In 2003, she obtained the Ph.D. degree in Experimental Physiopathology at the University of Rome Tor Vergata, where from 2003 to 2007 she worked as Postdoctoral Researcher at the Molecular Medicine Laboratory Department of Internal Medicine. The research carried out in recent years has focused on the study of the mechanisms involved in metabolic and cardiovascular pathologies, with particular emphasis to the identification of molecular mediators and biomarkers of endothelial dysfunction, atherosclerosis, and obesity-induced adipose tissue inflammation.